Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
The deal size was increased to $650M in common stock from $500M in common stock. JPMorgan, Jefferies, TD Cowen, Stifel, and William Blair acted as joint book running managers for the offering.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
See the top stocks recommended by analysts >>
Read More on XENE:
- Xenon Raises $650 Million in Upsized U.S. Equity Offering
- Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy
- Xenon Pharmaceuticals price target raised to $64 from $47 at Wedbush
- Xenon Pharmaceuticals price target raised to $90 from $60 at Guggenheim
- Xenon Pharmaceuticals price target raised to $68 from $49 at Wells Fargo
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
LAZARD, INC. <LAZ.N>: KBW CUTS TARGET PRICE TO $39.00 FROM $42.00
LAZARD, INC. : KBW CUTS TARGET PRICE TO $39.00 FROM $42.00
What Stocks Will Shine When the AI Bubble Bursts? John Rogers Says Look to Smucker's
GFL ENVIRONMENTAL INC. <GFL.TO>: CIBC CUTS TARGET PRICE TO C$77 FROM C$82
GFL ENVIRONMENTAL INC. : CIBC CUTS TARGET PRICE TO C$77 FROM C$82
Gold edges higher after hitting a two-month low
Crypto prices
More
